Industry News
Study Reveals Most Glaucoma Patients Unaware of Preservative-Free Treatment Options

A nationwide survey conducted by the Preservative Freedom Coalition highlights a critical gap in pat...

read more
Study Reveals Most Glaucoma Patients Unaware of Preservative-Free Treatment Options
March 14, 2025
RadiusXR and Glaukos Collaborate with Topcon to Inspire Visual Field Solution Launch

Topcon Healthcare, RadiusXR, and Glaukos have announced a strategic collaboration to launch Inspire,...

read more
RadiusXR and Glaukos Collaborate with Topcon to Inspire Visual Field Solution Launch
March 14, 2025
Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Development

Harrow has finalized a 5-year strategic supply and development (SSD) agreement to ensure the continu...

read more
Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Development
March 13, 2025
Kodiak Sciences Completes Enrollment in Phase 3 GLOW2 Trial of Tarcocimab Tedromer for Diabetic Retinopathy

Kodiak Sciences has successfully completed patient enrollment for its Phase 3 GLOW2 trial, evaluatin...

read more
Kodiak Sciences Completes Enrollment in Phase 3 GLOW2 Trial of Tarcocimab Tedromer for Diabetic Retinopathy
March 12, 2025
PER Launches Retina Resource: A Comprehensive Anti-VEGF Education Platform

Physicians’ Education Resource® (PER) has introduced Retina Resource, a specialized educational plat...

read more
PER Launches Retina Resource: A Comprehensive Anti-VEGF Education Platform
March 11, 2025
4DMT Enrolls First Patients in Phase 3 Clinical Trial of 4D-150 for Wet AMD

4D Molecular Therapeutics (4DMT) has officially commenced its Phase 3 clinical program for 4D-150, e...

read more
4DMT Enrolls First Patients in Phase 3 Clinical Trial of 4D-150 for Wet AMD
March 11, 2025
OKYO Pharma Seeks FDA Fast Track Designation for Urcosimod in Neuropathic Corneal Pain Treatment

OKYO Pharma has officially filed an application with the U.S. Food and Drug Administration (FDA) see...

read more
OKYO Pharma Seeks FDA Fast Track Designation for Urcosimod in Neuropathic Corneal Pain Treatment
March 11, 2025
Luxa Biotechnology Presents Promising Phase 1/2a Trial Data for RPESC-RPE-4W in Dry AMD

Luxa Biotechnology has presented clinical data from its Phase 1/2a trial evaluating RPESC-RPE-4W at ...

read more
Luxa Biotechnology Presents Promising Phase 1/2a Trial Data for RPESC-RPE-4W in Dry AMD
March 10, 2025
Lumata Health Secures $23 Million Series B Funding to Expand Vision-Saving Technology

Lumata Health has raised $23 million in Series B funding, bringing its total funding to $36 million ...

read more
Lumata Health Secures $23 Million Series B Funding to Expand Vision-Saving Technology
March 10, 2025
More